Drug intelligence / Profile preview

lactobacillus rhamnosus KL53A + bifidobacterium breve PB04

Development stage: Unknown
Lead developer: IBSS Biomed
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus rhamnosus KL53A + Bifidobacterium breve PB04 is a probiotic combination developed by IBSS BIOMED S.A. and marketed under the brand name FFbaby. The product contains two specific, patented bacterial strains of human origin, isolated from the feces of healthy, breastfed neonates. These strains are selected for their high adherence to intestinal cell lines, ability to survive the harsh environment of the stomach (gastric pH and bile), and their anti-inflammatory and antipathogenic properties. FFbaby is primarily used as a food for special medical purposes to support and restore the intestinal microbiome in infants and children, particularly those born preterm or via cesarean section. Clinical studies have demonstrated its efficacy in reducing the incidence of sepsis in low-birth-weight neonates and preventing gut dysbiosis by promoting the colonization of beneficial lactic acid bacteria.

Brand names: FFbaby
Other names: Lactobacillus rhamnosus KL53A + Bifidobacterium breve PB04

Beyond the preview

Go deeper on lactobacillus rhamnosus KL53A + bifidobacterium breve PB04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus rhamnosus KL53A + bifidobacterium breve PB04.

Explore the full profile